TherapeuticsMD Inc (TXMD) CFO Daniel A. Cartwright Sells 40,000 Shares
TherapeuticsMD Inc (NASDAQ:TXMD) CFO Daniel A. Cartwright sold 40,000 shares of the stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $4.85, for a total transaction of $194,000.00. Following the transaction, the chief financial officer now owns 40,000 shares in the company, valued at $194,000. The sale was disclosed in a filing with the SEC, which is available through this link.
TXMD stock opened at $4.76 on Wednesday. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -12.86 and a beta of 1.40. TherapeuticsMD Inc has a one year low of $4.30 and a one year high of $7.66. The company has a quick ratio of 7.15, a current ratio of 7.23 and a debt-to-equity ratio of 0.55.
TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Wednesday, November 7th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.06. The business had revenue of $3.47 million during the quarter, compared to analyst estimates of $4.43 million. TherapeuticsMD had a negative net margin of 757.59% and a negative return on equity of 102.15%. The company’s quarterly revenue was down 21.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.07) earnings per share. Analysts predict that TherapeuticsMD Inc will post -0.62 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in TXMD. Stevens Capital Management LP purchased a new stake in shares of TherapeuticsMD during the third quarter valued at about $101,000. Managed Account Services Inc. purchased a new stake in shares of TherapeuticsMD during the third quarter valued at about $117,000. Fox Run Management L.L.C. purchased a new stake in shares of TherapeuticsMD during the second quarter valued at about $121,000. Xact Kapitalforvaltning AB lifted its position in shares of TherapeuticsMD by 96.3% during the first quarter. Xact Kapitalforvaltning AB now owns 31,800 shares of the company’s stock valued at $155,000 after buying an additional 15,600 shares during the last quarter. Finally, Affiance Financial LLC purchased a new stake in shares of TherapeuticsMD during the second quarter valued at about $156,000. 66.24% of the stock is owned by institutional investors and hedge funds.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Featured Article: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.